Alpha-interferon in polycythemia vera and essential thrombocythemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myeloproliferative disorders (MPD) encompass conditions like polycythemia vera (PV) and essential thrombocythemia (ET).
• Conventional cytotoxic drugs are often used for MPD treatment, but novel therapeutic approaches are needed.
• Alpha-2a interferon (IFN) has emerged as a potential agent for MPD management.

Purpose of the Study:

• To evaluate the efficacy and safety of low-dose alpha-2a interferon (IFN) in patients with PV and ET.
• To assess treatment response in terms of hematological parameters, spleen size, and patient-reported outcomes.

Main Methods:

• A cohort of 21 patients (11 with PV, 10 with ET) received low-dose alpha-2a interferon (IFN).
• Patients included both newly diagnosed and previously treated individuals.
• Follow-up duration ranged from 4-22 months for PV and 4-16 months for ET.

Main Results:

• In PV patients, four achieved durable normal hematocrit, reduced platelet counts, and smaller spleen size within 4-8 weeks; three showed moderate disease control.
• In ET patients, five out of nine evaluable cases achieved complete response within six weeks, one had a partial response, and three showed no response.
• IFN therapy was generally well-tolerated, with only one ET patient discontinuing due to neurological side effects.

Conclusions:

• Low-dose alpha-2a interferon (IFN) demonstrates significant efficacy in a subset of patients with polycythemia vera (PV) and essential thrombocythemia (ET).
• IFN therapy is well-tolerated for long-term use in MPD patients.
• Further research is warranted to optimize IFN treatment strategies for MPD.